Back to Search
Start Over
Repeatability of deuterium metabolic imaging of healthy volunteers at 3 T.
- Source :
-
European radiology experimental [Eur Radiol Exp] 2024 Mar 13; Vol. 8 (1), pp. 44. Date of Electronic Publication: 2024 Mar 13. - Publication Year :
- 2024
-
Abstract
- Background: Magnetic resonance (MR) imaging of deuterated glucose, termed deuterium metabolic imaging (DMI), is emerging as a biomarker of pathway-specific glucose metabolism in tumors. DMI is being studied as a useful marker of treatment response in a scan-rescan scenario. This study aims to evaluate the repeatability of brain DMI.<br />Methods: A repeatability study was performed in healthy volunteers from December 2022 to March 2023. The participants consumed 75 g of [6,6'- <superscript>2</superscript> H <subscript>2</subscript> ]glucose. The delivery of <superscript>2</superscript> H-glucose to the brain and its conversion to <superscript>2</superscript> H-glutamine + glutamate, <superscript>2</superscript> H-lactate, and <superscript>2</superscript> H-water DMI was imaged at baseline and at 30, 70, and 120 min. DMI was performed using MR spectroscopic imaging on a 3-T system equipped with a <superscript>1</superscript> H/ <superscript>2</superscript> H-tuned head coil. Coefficients of variation (CoV) were computed for estimation of repeatability and between-subject variability. In a set of exploratory analyses, the variability effects of region, processing, and normalization were estimated.<br />Results: Six male participants were recruited, aged 34 ± 6.5 years (mean ± standard deviation). There was 42 ± 2.7 days between sessions. Whole-brain levels of glutamine + glutamate, lactate, and glucose increased to 3.22 ± 0.4 mM, 1.55 ± 0.3 mM, and 3 ± 0.7 mM, respectively. The best signal-to-noise ratio and repeatability was obtained at the 120-min timepoint. Here, the within-subject whole-brain CoVs were -10% for all metabolites, while the between-subject CoVs were -20%.<br />Conclusions: DMI of glucose and its downstream metabolites is feasible and repeatable on a clinical 3 T system.<br />Trial Registration: ClinicalTrials.gov, NCT05402566 , registered the 25th of May 2022.<br />Relevance Statement: Brain deuterium metabolic imaging of healthy volunteers is repeatable and feasible at clinical field strengths, enabling the study of shifts in tumor metabolism associated with treatment response.<br />Key Points: • Deuterium metabolic imaging is an emerging tumor biomarker with unknown repeatability.  • The repeatability of deuterium metabolic imaging is on par with FDG-PET.  • The study of deuterium metabolic imaging in clinical populations is feasible.<br /> (© 2024. The Author(s).)
Details
- Language :
- English
- ISSN :
- 2509-9280
- Volume :
- 8
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- European radiology experimental
- Publication Type :
- Academic Journal
- Accession number :
- 38472611
- Full Text :
- https://doi.org/10.1186/s41747-024-00426-4